TKNO
Alpha Teknova, Inc.Company Information
- Company Name
- Alpha Teknova, Inc.
- CIK
- CIK0001850902
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- TKNO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2835
- SIC Description
- In Vitro & In Vivo Diagnostic Substances
- Ticker
- TKNO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-06
- Last sale
- 2025-06-27
- Shares purchased (TTM)
- 66,000
- Shares sold (TTM)
- 8,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 9,089,869
- Shares outstanding
- 53,634,826
- Ownership
- 16.95%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 9.04%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 6 | 4 | 6 | 3 | 3 | 3 | 4 | 6 | 19 | 22 | 28 | 32 | ||||||
| Short Term Investments | 11 | 13 | 15 | 19 | 21 | 23 | 27 | 26 | - | - | 0 | - | ||||||
| Accounts Receivable Net Current | 5 | 6 | 5 | 5 | 5 | 6 | 4 | 5 | 5 | 5 | 4 | 5 | ||||||
| Income Taxes Receivable | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Inventory Net | 7 | 7 | 7 | 7 | 8 | 7 | 7 | 8 | 11 | 11 | 12 | 11 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | ||||||
| Assets Current | 31 | 32 | 35 | 37 | 38 | 40 | 43 | 46 | 35 | 39 | 46 | 51 | ||||||
| Property Plant And Equipment Net | 39 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 52 | ||||||
| Operating Lease Right Of Use Asset | 13 | 14 | 14 | 15 | 15 | 15 | 16 | 17 | 17 | 17 | 16 | 17 | ||||||
| Intangible Assets Net Excluding Goodwill | 11 | 12 | 12 | 12 | 13 | 13 | 13 | 13 | 14 | 14 | 14 | 17 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets | 96 | 99 | 104 | 108 | 110 | 114 | 119 | 124 | 115 | 121 | 129 | 138 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | ||||||
| Accrued Liabilities Current | 3 | 3 | 4 | 4 | 3 | 4 | 5 | 4 | 3 | 4 | 6 | 5 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Long Term Debt Current | - | - | 0 | 0 | 0 | 0 | 4 | 3 | 1 | - | 0 | - | ||||||
| Liabilities Current | 7 | 7 | 8 | 7 | 6 | 7 | 11 | 10 | 7 | 7 | 9 | 8 | ||||||
| Deferred Income Tax Liabilities Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Accrued Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Debt | 13 | 13 | 13 | 13 | 13 | 13 | 9 | 11 | 12 | 13 | 13 | 13 | ||||||
| Operating Lease Liability Noncurrent | 12 | 13 | 13 | 14 | 14 | 15 | 15 | 15 | 16 | 16 | 15 | 16 | ||||||
| Liabilities | 33 | 34 | 35 | 35 | 34 | 35 | 36 | 37 | 36 | 37 | 39 | 39 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 206 | 205 | 205 | 204 | 203 | 202 | 201 | 200 | 184 | 183 | 182 | 181 | ||||||
| Retained Earnings Accumulated Deficit | -144 | -140 | -136 | -131 | -127 | -123 | -119 | -113 | -105 | -100 | -92 | -81 | ||||||
| Stockholders Equity | 63 | 65 | 69 | 73 | 76 | 79 | 82 | 87 | 79 | 83 | 90 | 100 | ||||||
| Liabilities And Stockholders Equity | 96 | 99 | 104 | 108 | 110 | 114 | 119 | 124 | 115 | 121 | 129 | 138 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | ||||||
| Common Stock Shares Issued | 54 | 54 | 54 | 54 | 54 | 53 | 53 | 53 | 41 | 41 | 41 | 41 | ||||||
| Shares Outstanding | 54 | 54 | 54 | 54 | 54 | 53 | 53 | 53 | 41 | 41 | 41 | 41 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAlpha Teknova, Inc. (TKNO) — SEC Financial Statements & Analysis
Alpha Teknova, Inc. (TKNO) is a in vitro & in vivo diagnostic substances company, incorporated in DE. Alpha Teknova, Inc. trades on Nasdaq as: TKNO. Alpha Teknova, Inc. (TKNO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Alpha Teknova, Inc. carries a market cap of $304.65M, a P/E ratio of -18.17x, a P/B ratio of 4.87x, a P/S ratio of 6.97x, an enterprise value of $311.86M, and an EV/EBITDA multiple of -32.92x. On profitability, it posts a gross margin of 34.60%, an operating margin of -36.19%, a net margin of -38.37%, a Return on Equity (ROE) of -24.19%, a Return on Assets (ROA) of -16.25%, and a Return on Invested Capital (ROIC) of -20.11%. Per share, it reports EPS of $-0.31, diluted EPS of $-0.31, free cash flow per share of $-0.14, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 12.27% year-over-year, net income growth of -22.00% year-over-year, and EPS growth of -22.27% year-over-year. On the balance sheet, it maintains a current ratio of 4.49x, a quick ratio of 3.32x, working capital of $23.95M, a debt-to-equity ratio of 0.53x, a debt ratio of 0.35, an interest coverage ratio of -18.14x, free cash flow of $-7.35M (TTM), and net debt of $7.21M. Figures sourced from SEC EDGAR.
- Market Cap
- $304.65M
- P/E TTM
- -18.17x
- EPS TTM
- $-0.31
- P/B TTM
- 4.87x
- ROE TTM
- -24.19%
- ROA TTM
- -16.25%
- Debt To Equity
- 0.53x
- Free Cash Flow TTM
- $-7.35M
- Net Revenue TTM Growth 1Y
- 12.27%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Alpha Teknova, Inc. in?
Alpha Teknova, Inc. (TKNO) operates in the In Vitro & In Vivo Diagnostic Substances industry.
What exchange does TKNO trade on?
Alpha Teknova, Inc. (TKNO) trades on the Nasdaq.
Where is Alpha Teknova, Inc. incorporated?
Alpha Teknova, Inc. is incorporated in DE.
When was Alpha Teknova, Inc. (TKNO)'s most recent SEC filing?
Alpha Teknova, Inc. (TKNO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is TKNO's market cap?
Alpha Teknova, Inc. (TKNO) has a market capitalization of $304.65M as of 2026-06-30.
What is TKNO's EPS (earnings per share)?
Alpha Teknova, Inc. (TKNO)'s trailing twelve month EPS is $-0.31 as of 2026-06-30.
What is TKNO's ROE (return on equity)?
Alpha Teknova, Inc. (TKNO)'s trailing twelve month Return on Equity (ROE) is -24.19% as of 2026-06-30.
What is TKNO's ROA (return on assets)?
Alpha Teknova, Inc. (TKNO)'s trailing twelve month Return on Assets (ROA) is -16.25% as of 2026-06-30.
What is TKNO's ROIC (return on invested capital)?
Alpha Teknova, Inc. (TKNO)'s trailing twelve month Return on Invested Capital (ROIC) is -20.11% as of 2026-06-30.
What is TKNO's EV/EBITDA?
Alpha Teknova, Inc. (TKNO)'s trailing twelve month EV/EBITDA is -32.92x as of 2026-06-30.